For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Group newsletter: CCTG Connection

Archived Bulletins

October 07, 2020

Published: October 07, 2020
Category: Trials
OVC2(NCT02502266) : A Randomized Phase II/III study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) has closed to accrual after successfully reaching the accrual goal.
 
About the trial
Read More

Published: October 07, 2020
Category: Group updates
Biniam Kidane

Congrats to CCTG investigator Biniam Kidane for his recognition award, the Aubie Angel Young Investigator Award in Clinical Research: This represents the University of Manitoba’s highest award for young faculty members who have attained a national and international reputation in their research accomplishments.

Read More

Published: October 07, 2020
Category: Publications
Publication: CommNETs and NANETS Guidelines

CommNETs and NANETS Guidelines for the Diagnosis and Management of Patients with Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 ENETS Expert Consensus Guidelines

Read More

Published: October 07, 2020
Category: Publications
Publication: MA31
The purpose of this retrospective biomarker study of the Canadian Cancer Trials Group (CCTG) MA.31 randomized phase 3 trial (lapatinib vs trastuzumab) of HER2‐positive metastatic breast cancer (MBC) was to evaluate the prognostic and predictive biomarker utility of pretreatment serum programmed death ligand 1 (PD‐L1) levels.
 
Read More

September 23, 2020

The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.

Read More

Published: September 23, 2020
Category: Publications

The results for the CCTG PA7 trial were recently presented at the European Society for Medical Oncology (ESMO) virtual Congress. The CCTG lead for this study, Dr. Daniel Renouf, reported on key results of the PA7 Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line study.

Read More

Published: September 23, 2020
Category: Publications

Publication for BL12: A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen

Read More

Published: September 23, 2020
Category: Other
Dr. Libni Joseph Eapen passing

CCTG would like to extend condolences to the family, friends, and colleagues of Dr. Libni Joseph Eapen who passed suddenly last week.  Dr. Eapen was a researcher and radiation oncologist at the Ottawa Cancer Centre for the entirety of his career, he dedicated his 66 years to learning, teaching, humour and healing.

Condolences can be left on his obituary page https://www.dignitymemorial.com/obituaries/ottawa-on/libni-eapen-9358605

Read More